Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

Among women aged 27–45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was also generally well tolerated and highly immunogenic i...

Full description

Bibliographic Details
Main Authors: Ivette Maldonado, Manuel Plata, Mauricio Gonzalez, Alfonso Correa, Claudia Nossa, Anna R. Giuliano, Elmar A. Joura, Alex Ferenczy, Brigitte M. Ronnett, Mark H. Stoler, Hao Jin Zhou, Amita Joshi, Rituparna Das, Oliver Bautista, Thomas Group, Alain Luxembourg, Alfred Saah, Ulrike Kirsten Buchwald
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
clinical trial
effectiveness
human papillomavirus
immunogenicity
mid-adult persons
qhpv vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2022.2078626

Internet

http://dx.doi.org/10.1080/21645515.2022.2078626

Similar Items